Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WAI YUEN TONG MEDICINE HOLDINGS LIMITED

(位元堂藥業控股有限公司*)

(Incorporated in Bermuda with limited liability)
(Stock Code: 897)

POLL RESULTS OF SPECIAL GENERAL MEETING HELD ON 23 MARCH 2011 IN RELATION TO PROPOSED SHARE PREMIUM REDUCTION, REFRESHMENT OF NEW GENERAL MANDATE AND NEW REPURCHASE MANDATE

The Board is pleased to announce that the resolutions set out in the SGM Notice to approve the Proposed Share Premium Reduction, the granting of the New General Mandate, and the extension thereof, and the New Repurchase Mandate were duly passed by the Shareholders at the SGM held on 23 March 2011 by way of poll.

Reference is made to the circular of Wai Yuen Tong Medicine Holdings Limited (the "Company") dated 28 February 2011 (the "Circular") in relation to the Proposed Share Premium Reduction, the granting of the New General Mandate and the New Repurchase Mandate. Capitalised terms used herein shall have the same meanings as defined in the Circular unless otherwise stated.

POLL RESULTS OF THE SGM

The Board is pleased to announce that the resolutions set out in the notice of the SGM dated 28 February 2011 (the "SGM Notice") to approve the Proposed Share Premium Reduction, the granting of the New General Mandate, and the extension thereof, and the New Repurchase Mandate were duly passed by the Shareholders at the SGM held on 23 March 2011 by way of poll. The Company's branch share registrar and transfer office in Hong Kong, Tricor Secretaries Limited, was appointed as the scrutineer for the vote-taking at the SGM.

^{*} For identification purpose only

The poll results in respect of resolutions proposed at the SGM are as follows:

	Number of Shares (Approximate % of total number of votes present and voted at the SGM)		Total number of
Special Resolution	For	Against	Shares voted
1. To approve the Proposed Share Premium	253,662,079	1,090,000	254,752,079
Reduction	(99.57%)	(0.43%)	(100%)
Ordinary Resolutions			
2. To approve the granting of the New	250,939,965	3,812,114	254,752,079
General Mandate	(98.50%)	(1.50%)	(100%)
3. To approve the granting of the New	253,662,079	1,090,000	254,752,079
Repurchase Mandate	(99.57%)	(0.43%)	(100%)
4. To approve the extension of the New	250,939,965	3,812,114	254,752,079
General Mandate	(98.50%)	(1.50%)	(100%)

Note: The full text of the above resolutions proposed at the SGM is set out in the SGM Notice.

As at the date of the SGM, the Company had no controlling Shareholders and that no Directors (excluding the independent non-executive Directors), the chief executive of the Company and their respective associates held any Shares. Accordingly, none of the Shareholders is required to abstain from voting on the proposed resolutions as set out in the SGM Notice. No Shareholder was entitled to attend and vote only against the resolutions at the SGM, nor did any Shareholder state their intention in the Circular to vote against the resolutions or to abstain.

As at the date of the SGM, the number of issued shares of the Company was 2,036,142,969 Shares, which was the total number of Shares entitling the holders to attend and vote for or against the resolutions proposed at the SGM.

By Order of the Board

Wai Yuen Tong Medicine Holdings Limited
(位元堂藥業控股有限公司*)

Chan Chun Hong, Thomas

Managing Director

Hong Kong, 23 March 2011

As at the date of this announcement, the Board comprises three executive Directors, namely Mr. Tang Ching Ho, Mr. Chan Chun Hong, Thomas and Ms. Tang Mui Fun, and four independent non-executive Directors, namely Mr. Leung Wai Ho, Mr. Siu Man Ho, Simon, Mr. Yuen Chi Choi and Mr. Cho Wing Mou.

^{*} For identification purpose only